Video

Dr. Finn Discusses Sequencing Therapy for HCC

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses sequencing therapy for patients with hepatocellular carcinoma.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses sequencing therapy for patients with hepatocellular carcinoma (HCC).

The last 1.5 years has brought about multiple positive phase III data regarding treatment for patients with HCC, says Finn. If these drugs are approved, the next step is figuring out how to optimally sequence therapy with other recently approved agents like regorafenib (Stivarga) and nivolumab (Opdivo). There is currently no high-level data to advise how to sequence.

Finn says that advanced HCC occurs in the setting of advanced cirrhosis, so it is important to identify patients appropriately to optimize their sequencing. In the past, when few drugs were available, patients would receive locoregional therapy beyond what was suggested, says Finn. This continued to occur with sorafenib (Nexavar), and patients were not transitioned to systemic treatment at an appropriate time. Finn says that patients should be transitioned when they have radiographic progression, not clinical progression or decompensation. This is more important now with these new drugs available, because if a patient is too ill from their underlying cirrhosis, then getting them to the second- and third-line will be difficult or impossible.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity